Mode
Text Size
Log in / Sign up

Meta-analysis finds cerebral embolic protection does not reduce stroke in TAVR patientsNew review shows brain protection devices did not lower stroke risk for heart valve patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that cerebral embolic protection may not reduce stroke risk in TAVR based on current meta-analytic evidence.

This is a systematic review and meta-analysis of studies on cerebral embolic protection (CEP) devices in patients undergoing transcatheter aortic valve replacement (TAVR). The analysis synthesized data from 11,696 patients, with 6,000 in the CEP group and 5,696 in the control group receiving no protection.

The primary finding was that CEP use did not significantly reduce the overall risk of all-cause stroke, with a pooled relative risk of 0.92 (95% CI 0.73 to 1.14; p = 0.43). The authors also reported no significant differences between groups for secondary outcomes, including all-cause mortality, disabling stroke, non-disabling stroke, cardiovascular mortality, transient ischemic attack, major adverse cardiovascular and cerebrovascular events, major bleeding, major vascular complications, and acute kidney injury.

The review did not report specific limitations, safety data, or follow-up duration. The authors did not quantify heterogeneity or detail the included study designs. Given the lack of significant effect on the primary outcome and most secondary outcomes, the practice relevance for routine CEP use in TAVR appears limited based on this synthesis.

Doctors looked at data from more than eleven thousand patients who had a new heart valve placed through a small cut in their groin. This procedure is called transcatheter aortic valve replacement. Some patients got special filters to catch clots, while others did not get this extra protection.

The main question was whether the filters would stop strokes. The study found that patients with filters did not have fewer strokes than those without them. The chance of having a stroke was about the same in both groups. This was true for all types of strokes and for dying from any cause.

Other health outcomes were also checked. There were no differences in heart attacks, kidney problems, or bleeding between the two groups. The study looked at many different health results to see if the filters helped in any way. The answer was no for most of these important health measures.

This research helps doctors decide if these extra devices are necessary. Since the filters did not make a difference, they might not be needed for every patient. This could mean simpler surgeries with fewer devices for many people in the future.

What this means for you:
Filters used during heart valve surgery did not lower stroke risk or death rates compared to not using them.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundCerebral embolic protection (CEP) devices have been developed to reduce periprocedural embolization through transcatheter aortic valve replacement (TAVR), yet their clinical benefit remains uncertain. This study aimed to systematically evaluate the efficacy and safety of CEP devices during TAVR using evidence restricted to randomized controlled trials (RCTs).MethodsWe conducted a systematic review and meta-analysis following PRISMA guidelines. MEDLINE, Embase, Web of Science, Scopus, and Cochrane CENTRAL were searched through July 2025 for RCTs comparing CEP devices vs. no protection in patients undergoing TAVR. The primary outcome was the all-cause stroke. Random-effects model was applied for the primary analysis.ResultsNine RCTs comprising 11,696 patients (6,000 patients in CEP, 5,696 patients in control) were analyzed. CEP use did not significantly reduce the overall risk of all-cause stroke (RR 0.92; 95% CI 0.73–1.14; p = 0.43). The results were consistent across different subgroups, either Sentinel (filter device) (RR 0.88; 95% CI 0.70–1.11; I2 = 0.00%) or TriGuard (deflection device) (RR 1.40; 95% CI 0.67–2.94; I2 = 0.00%) (Pinteraction = 0.50). Similarly, no significant differences between the two groups were observed for the risk of all-cause mortality, disabling stroke, non-disabling stroke, cardiovascular mortality, transient ischemic attack, major adverse cardiovascular and cerebrovascular events, major bleeding, major vascular complications, or acute kidney injury.ConclusionsAmong patients undergoing TAVR, CEP devices could not reduce the risk of stroke compared with the control group.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251114450, CRD420251114450.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.